Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation

Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation

Background—Known risk factors for bleeding during anticoagulant treatment are largely the same as those predicting thromboembolic events in patients with atrial fibrillation (AF). Our objective was to investigate how to maximize the likelihood of avoiding both stroke and bleeding. Methods and Results—All 182 678 subjects with atrial fibrillation in the Swedish Hospital Discharge Register were s...

Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation.

BACKGROUND Little is known about the net clinical benefit of warfarin therapy in elderly patients with atrial fibrillation. METHODS AND RESULTS We studied 2339 Chinese patients with nonvalvular atrial fibrillation aged≥80 years: 1805 with no antithrombotic therapy and 534 on warfarin therapy. Patients were stratified according to their CHA2DS2-VASc and HAS-BLED score. The primary end point wa...

Warfarin in haemodialysis patients with atrial fibrillation: what benefit?

Warfarin is commonly used to prevent stroke in patients with atrial fibrillation; however, patients on haemodialysis may not derive the same benefit from warfarin as the general population. There are no randomized controlled studies in dialysis patients which demonstrate the efficacy of warfarin in preventing stroke. In fact, warfarin places the dialysis patient at increased risk for haemorrhag...

Net clinical benefit of warfarin: extending the reach of antithrombotic therapy for atrial fibrillation.

The Net Clinical Benefit of Warfarin : Extending the Reach of Antithrombotic Therapy for Atrial Fibrillation